Study wrapper · #967
CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.
Verma S, Böttcher M, Brown P, et al. Hypertension. 2026.
DOI: 10.1161/hypertensionaha.125.26055PubMed: 41328546
Editor's note
A secondary and post hoc analysis of the 68-week REDEFINE 1 phase 3 trial (3417 participants) examining blood pressure. CagriSema was associated with systolic reductions of about 11 mm Hg versus under 3 mm Hg for placebo, including among participants with resistant hypertension. Strong human evidence for a cardiometabolic secondary endpoint.
Plain-language abstract
In this phase 3 trial analysis, the cagrilintide-semaglutide combination was associated with larger blood pressure reductions than placebo in adults with overweight or obesity.
Related coverage
Mixed
Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy?
Lancet (London, England)n=——2026
Supported
Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.
Physiology & behaviorn=——2026
Supported
Maximizing weight loss with cagrisema: a systematic review and GRADE-assessed meta-analysis of randomized controlled trials.
Naunyn-Schmiedeberg's archives of pharmacologyn=——2026